ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00291304
Recruitment Status : Terminated
First Posted : February 14, 2006
Last Update Posted : February 24, 2016
Sponsor:
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta

Brief Summary:
Magnetic Resonance Imaging (MRI) is a well known imaging tool for the investigation and diagnosis of breast cancer, used in addition to breast mammograms and ultrasound. Recent publications suggest that MRI may be the best test to use in women who have very dense breasts, have a family history of breast cancer and have had breast cancer and were treated with breast saving measures. MRI has been shown to be a better tool to show multiple breast cancer spots than mammography or ultrasound. The radiologists and the radiology students will have the opportunity to review the MRI scans along with the breast ultrasound and mammography films and the pathology reports from the breast cancer surgery completed at the CCI. This may enable them to learn how the various subtypes of breast cancer look on MRI. The goal is: 1) to gain good breast MRI expertise, giving the Radiology residents a complete diagnostic program. 2) to develop good MRI breast experience, enabling the Cross Cancer Institute to be the centre of excellence for Breast MRI for northern Alberta.

Condition or disease Intervention/treatment Phase
-Breast Neoplasms Procedure: MRI Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma
Study Start Date : March 2006
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources


Intervention Details:
    Procedure: MRI
    pre-surgery


Primary Outcome Measures :
  1. -assess how MRI of the breast correlates to standard of care which includes ultrasound, mammography, biopsy and surgery [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. -assess how the MRO correlates to the breast cancer pathology collected at the CCI [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • females 18 years or older
  • females referred to Dr. Kelly Dabbs for breast cancer surgery with pathology positive for breast carcinoma, any subtype

Exclusion Criteria:

  • pacemakers
  • aneurysm clips
  • cochlear implants
  • epicardial pacemaker wires
  • neural stimulators, etc.
  • significant claustrophobia
  • significant obesity that would not enable the patient to fit in the scanner
  • pregnancy or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00291304


Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Investigators
Principal Investigator: Barbara Campbell, MD AHS Cancer Control Alberta

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00291304     History of Changes
Other Study ID Numbers: BR-1-0082
First Posted: February 14, 2006    Key Record Dates
Last Update Posted: February 24, 2016
Last Verified: December 2011

Keywords provided by AHS Cancer Control Alberta:
Magnetic Resonance Imaging
Pathology

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases